-
Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial Lancet Oncol. (IF 51.1) Pub Date : 2024-03-08 Arnon P Kater MD, Önder Arslan MD, Fatih Demirkan MD, Yair Herishanu MD, Burhan Ferhanoglu MD, Marcos Gonzalez Diaz MD, Brian Leber MD, Marco Montillo MD, Panayiotis Panayiotidis MD, Davide Rossi PhD, Alan Skarbnik MD, Adrian Tempescul PhD, Mehmet Turgut MD, Clemens H Mellink PhD, Anne-Marie F van der Kevie-Kersemaekers PhD, Stuart Lanham PhD, Ben Sale MSc, Luis Del Rio MSc, Relja Popovic MD, Brenda
Most patients with chronic lymphocytic leukaemia progress after treatment or retreatment with targeted therapy or chemoimmunotherapy and have limited subsequent treatment options. Response levels to the single-agent venetoclax in the relapsed setting is unknown. We aimed to assess venetoclax activity in patients with or without previous B-cell receptor-associated kinase inhibitor (BCRi) treatment.
-
Alabama Supreme Court's “extrauterine children” decision alarms oncologists and fertility experts Lancet Oncol. (IF 51.1) Pub Date : 2024-03-07 B, r, y, a, n, t, , F, u, r, l, o, w
-
Non-communicable diseases in humanitarian settings Lancet Oncol. (IF 51.1) Pub Date : 2024-03-07 T, a, l, h, a, , B, u, r, k, i
-
Innovation in gynaecological cancer: highlighting global disparities Lancet Oncol. (IF 51.1) Pub Date : 2024-03-07 Maria Kyrgiou, Sarah Bowden, Lynette Denny, Anna Fagotti, Nadim R Abu-Rustum, Pedro T Ramirez, Denis Querleu
-
Correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer: an FDA pooled analysis Lancet Oncol. (IF 51.1) Pub Date : 2024-03-05 Bernardo Haddock Lobo Goulart MD, Sirisha L Mushti PhD, Somak Chatterjee PhD, Erin Larkins MD, Pallavi S Mishra-Kalyani PhD, Richard Pazdur MD, Paul G Kluetz MD, Harpreet Singh MD
Radiographic changes might not fully capture the treatment effects of immune checkpoint inhibitors (ICIs). We aimed to assess correlations of overall response rate and progression-free survival with overall survival in trials of ICIs for metastatic non-small-cell lung cancer (NSCLC). To assess trial-level and patient-level correlations of overall response rate and progression-free survival with overall
-
Children and Young People Cancer Taskforce Lancet Oncol. (IF 51.1) Pub Date : 2024-02-15 Talha Burki
-
The multitarget faecal immunochemical test for improving stool-based colorectal cancer screening programmes: a Dutch population-based, paired-design, intervention study Lancet Oncol. (IF 51.1) Pub Date : 2024-02-09 Pieter H A Wisse, Willemijn de Klaver, Francine van Wifferen, Frejanne G van Maaren-Meijer, Huub E van Ingen, Lana Meiqari, Iris Huitink, Mariska Bierkens, Margriet Lemmens, Marjolein J E Greuter, Monique E van Leerdam, Manon C W Spaander, Evelien Dekker, Veerle M H Coupé, Beatriz Carvalho, Meike de Wit, Gerrit A Meijer
-
Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial Lancet Oncol. (IF 51.1) Pub Date : 2024-02-09 Carlo Palmieri, Hannah Linden, Stephen N Birrell, Sally Wheelwright, Elgene Lim, Lee S Schwartzberg, Amy R Dwyer, Theresa E Hickey, Hope S Rugo, Patrick Cobb, Joyce A O'Shaughnessy, Stephen Johnston, Adam Brufsky, Wayne D Tilley, Beth Overmoyer
-
Treatment of metastatic pancreatic cancer: 25 years of innovation with little progress for patients Lancet Oncol. (IF 51.1) Pub Date : 2024-01-29 Bishal Gyawali, Christopher M Booth
Abstract not available
-
Modelling radiotherapy availability in the Asia-Pacific region Lancet Oncol. (IF 51.1) Pub Date : 2024-01-29 Yolande Lievens
Abstract not available
-
Accelerating progress on EU cancer control Lancet Oncol. (IF 51.1) Pub Date : 2024-01-29 Andreas Charalambous, Richard Price, Prabhat Jha
Abstract not available
-
Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein–Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial Lancet Oncol. (IF 51.1) Pub Date : 2024-01-31 Kris Michael Mahadeo, Robert Baiocchi, Amer Beitinjaneh, Sridhar Chaganti, Sylvain Choquet, Daan Dierickx, Rajani Dinavahi, Xinyuan Duan, Laurence Gamelin, Armin Ghobadi, Norma Guzman-Becerra, Manher Joshi, Aditi Mehta, Willis H Navarro, Sarah Nikiforow, Richard J O'Reilly, Ran Reshef, Fiona Ruiz, Tassja Spindler, Susan Prockop
Background Survival in Epstein–Barr virus (EBV)-positive post-transplant lymphoproliferative disease following haematopoietic stem-cell transplant (HSCT) or solid organ transplant (SOT) is poor after failure of initial therapy, indicating an urgent need for therapies for this ultra-rare disease. With recent EU marketing authorisation, tabelecleucel is the first off-the-shelf, allogeneic, EBV-specific
-
IAEA site visit to the Zaporizhzhya Nuclear Power Plant in Ukraine Lancet Oncol. (IF 51.1) Pub Date : 2024-02-02 Manjulika Das
Abstract not available
-
HPV vaccination programme success in Scotland Lancet Oncol. (IF 51.1) Pub Date : 2024-02-02 Talha Burki
Abstract not available
-
Strategies to promote sustainable care for children with cancer in Ukraine Lancet Oncol. (IF 51.1) Pub Date : 2024-01-30 Asya Agulnik, Yuliya Nogovitsyna, Roman Kizyma, Taisiya Yakimkova, Victoria Vivtcharenko, Nickhill Bhakta, Paul H Wise, Carlos Rodriguez-Galindo, Arman Kacharian
Abstract not available
-
Design and implementation of a humanitarian cancer care programme for Ukrainian refugees in Moldova and Romania Lancet Oncol. (IF 51.1) Pub Date : 2024-01-30 Horia Vulpe, Artiom Minzatean, Irena Tocino, Ruslan Baltaga, Gabriel Kacso, Claudia Oprea, Veronica Ciobanu, Sergiu Brenister, Ciprian Tomuleasa, Gabriel Ricu, Rodica Mindruta-Stratan, Catalin Danaila, Dragos Iancu, Ludmila Circiumari, Cristian Teglas, Lars Lonnback, Violina Nazaria, Ursula Wagner, Eugenia Ciubotaru, Nicoleta Minzatean, Stefania Magidson
Abstract not available
-
Complete cancer prevalence in Europe in 2020 by disease duration and country (EUROCARE-6): a population-based study Lancet Oncol. (IF 51.1) Pub Date : 2024-01-30 Roberta De Angelis, Elena Demuru, Paolo Baili, Xavier Troussard, Alexander Katalinic, Maria Dolores Chirlaque Lopez, Kaire Innos, Mariano Santaquilani, Marcel Blum, Leonardo Ventura, Keiu Paapsi, Rocco Galasso, Marcela Guevara, Giorgia Randi, Manola Bettio, Laura Botta, Stefano Guzzinati, Luigino Dal Maso, Silvia Rossi, , Dyfed Wyn Huws
Background Cancer survivors—people living with and beyond cancer—are a growing population with different health needs depending on prognosis and time since diagnosis. Despite being increasingly necessary, complete information on cancer prevalence is not systematically available in all European countries. We aimed to fill this gap by analysing population-based cancer registry data from the EUROCARE-6
-
Immunotherapy: balancing the risks and benefits Lancet Oncol. (IF 51.1) Pub Date : 2024-01-29
Abstract not available
-
Multiplex immunofluorescence for tumour immune biomarker discovery Lancet Oncol. (IF 51.1) Pub Date : 2024-01-29 Juha P Väyrynen
Abstract not available
-
Thank you to The Lancet Oncology's reviewers in 2023 Lancet Oncol. (IF 51.1) Pub Date : 2024-01-29
Abstract not available
-
Pembrolizumab plus chemotherapy for advanced gastric cancer Lancet Oncol. (IF 51.1) Pub Date : 2024-01-29 Chen-yu Huang, Xiao-bing Wu
Abstract not available
-
Pembrolizumab plus chemotherapy for advanced gastric cancer Lancet Oncol. (IF 51.1) Pub Date : 2024-01-29 Tim Schutte, Sarah Derks, Hanneke W M van Laarhoven
Abstract not available
-
Pembrolizumab plus chemotherapy for advanced gastric cancer – Authors' reply Lancet Oncol. (IF 51.1) Pub Date : 2024-01-29 Sun Young Rha, Sonal Bordia
Abstract not available
-
Classifying and grading liposarcoma by CT Lancet Oncol. (IF 51.1) Pub Date : 2024-01-29 Tomomi Sanomachi, Hiroto Ishiki
Abstract not available
-
The GLOW trial in chronic lymphocytic leukaemia Lancet Oncol. (IF 51.1) Pub Date : 2024-01-29 Martin Fey
Abstract not available
-
The GLOW trial in chronic lymphocytic leukaemia Lancet Oncol. (IF 51.1) Pub Date : 2024-01-29 Michel van Gelder, Mels Hoogendoorn, Doreen te Raa
Abstract not available
-
The GLOW trial in chronic lymphocytic leukaemia – Authors' reply Lancet Oncol. (IF 51.1) Pub Date : 2024-01-29 Carsten U Niemann, Arnon P Kater
Abstract not available
-
Primary ovarian insufficiency prediction in adult survivors of childhood cancer: model concerns Lancet Oncol. (IF 51.1) Pub Date : 2024-01-29 William Hamish B Wallace, Tom W Kelsey
Abstract not available
-
Primary ovarian insufficiency prediction in adult survivors of childhood cancer: model concerns Lancet Oncol. (IF 51.1) Pub Date : 2024-01-29 Fangjieyi Zheng, Kening Chen, Wenquan Niu
Abstract not available
-
Primary ovarian insufficiency prediction in adult survivors of childhood cancer: model concerns – Authors' reply Lancet Oncol. (IF 51.1) Pub Date : 2024-01-29 Cindy Im, Zhe Lu, Yutaka Yasui, Melissa M Hudson, Kirsten K Ness, Gregory T Armstrong, Sogol Mostoufi-Moab, Yan Yuan
Abstract not available
-
Correction to Lancet Oncol 2020; 21: 796–807 Lancet Oncol. (IF 51.1) Pub Date : 2024-01-29
Abstract not available
-
Correction to Lancet Oncol 2023; 24: 1018–28 Lancet Oncol. (IF 51.1) Pub Date : 2024-01-29
Abstract not available
-
World Oncology Forum amplifies its appeal in global fight against cancer Lancet Oncol. (IF 51.1) Pub Date : 2024-01-29 Franco Cavalli, Bente Mikkelsen, Elisabete Weiderpass, Richard Sullivan, David Jaffray, Mary Gospodarowicz
Abstract not available
-
Multiplex analysis of intratumoural immune infiltrate and prognosis in patients with stage II–III colorectal cancer from the SCOT and QUASAR 2 trials: a retrospective analysis Lancet Oncol. (IF 51.1) Pub Date : 2024-01-29 Anja L Frei, Anthony McGuigan, Ritik R A K Sinha, Faiz Jabbar, Luciana Gneo, Tijana Tomasevic, Andrea Harkin, Tim Iveson, Mark P Saunders, Karin A Oien, Noori Maka, Francesco Pezzella, Leticia Campo, Molly Browne, Mark Glaire, Wanja Kildal, Havard E Danielsen, Jennifer Hay, Joanne Edwards, Owen Sansom, Viktor H Koelzer
Background Tumour-infiltrating CD8+ cytotoxic T cells confer favourable prognosis in colorectal cancer. The added prognostic value of other infiltrating immune cells is unclear and so we sought to investigate their prognostic value in two large clinical trial cohorts. Methods We used multiplex immunofluorescent staining of tissue microarrays to assess the densities of CD8+, CD20+, FoxP3+, and CD68+
-
Current and projected gaps in the availability of radiotherapy in the Asia-Pacific region: a country income-group analysis Lancet Oncol. (IF 51.1) Pub Date : 2024-01-29 Dania Abu Awwad, Jesmin Shafiq, Geoffrey Paul Delaney, Yavuz Anacak, Freddie Bray, Jerickson Abbie Flores, Soehartati Gondhowiardjo, Minjmaa Minjgee, Tiara Bunga Mayang Permata, Jaffar C Pineda, Suhana Yusak, Eduardo Zubizarreta, Mei Ling Yap
Background Cancer incidence and mortality is increasing rapidly worldwide, with a higher cancer burden observed in the Asia-Pacific region than in other regions. To date, evidence-based modelling of radiotherapy demand has been based on stage data from high-income countries (HIC) that do not account for the later stage at presentation seen in many low-income and middle-income countries (LMICs). We
-
Quality indicators for evaluating cancer care in low-income and middle-income country settings: a multinational modified Delphi study Lancet Oncol. (IF 51.1) Pub Date : 2024-01-29 Megan McLeod, Julie Torode, Kari Leung, Nirmala Bhoo-Pathy, Christopher Booth, Jade Chakowa, Julie Gralow, Andre Ilbawi, Jacek Jassem, Jeannette Parkes, Merixtell Mallafré-Larrosa, Miriam Mutebi, CS Pramesh, Manju Sengar, Audrey Tsunoda, Karla Unger-Saldaña, Verna Vanderpuye, Aasim Yusuf, Richard Sullivan, Ajay Aggarwal
This Policy Review sourced opinions from experts in cancer care across low-income and middle-income countries (LMICs) to build consensus around high-priority measures of care quality. A comprehensive list of quality indicators in medical, radiation, and surgical oncology was identified from systematic literature reviews. A modified Delphi study consisting of three 90-min workshops and two international
-
International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations Lancet Oncol. (IF 51.1) Pub Date : 2024-01-29 Icro Meattini, Carlotta Becherini, Saverio Caini, Charlotte E Coles, Javier Cortes, Giuseppe Curigliano, Evandro de Azambuja, Clare M Isacke, Nadia Harbeck, Orit Kaidar-Person, Elisabetta Marangoni, Birgitte V Offersen, Hope S Rugo, Viola Salvestrini, Luca Visani, Andrea Morandi, Matteo Lambertini, Philip Poortmans, Lorenzo Livi, , Tanja Spanic
Novel systemic therapies for breast cancer are being rapidly implemented into clinical practice. These drugs often have different mechanisms of action and side-effect profiles compared with traditional chemotherapy. Underpinning practice-changing clinical trials focused on the systemic therapies under investigation, thus there are sparse data available on radiotherapy. Integration of these new systemic
-
Cancer care and treatment during homelessness Lancet Oncol. (IF 51.1) Pub Date : 2024-01-29 Ramin Asgary
People experiencing homelessness have not yet benefited from the substantial progress made in managing cancers, including advances in chemotherapy and radiotherapy, surgical interventions, multidisciplinary team approaches, and integrated cancer care models. People experiencing homelessness are at higher risks of developing cancers and their mortality due to cancer is twice that of the general population
-
Cutaneous blisters mimicking bullous pemphigoid Lancet Oncol. (IF 51.1) Pub Date : 2024-01-29 Yue-Qian Yu, Jing Wen, Xue-Chao Chen, Hong Liu, Fu-Ren Zhang
Abstract not available
-
Substance use disorders among cancer survivors Lancet Oncol. (IF 51.1) Pub Date : 2024-01-25 Sharmila Devi
Abstract not available
-
US radiation oncology organisations work towards Medicare payment reform Lancet Oncol. (IF 51.1) Pub Date : 2024-01-18 Manjulika Das
Abstract not available
-
Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trial Lancet Oncol. (IF 51.1) Pub Date : 2024-01-12 Jyoti Bajpai, Venkatesh Kapu, Sushmita Rath, Sravan Kumar, Anbarasan Sekar, Priyanka Patil, Altaf Siddiqui, Srikanth Anne, Akash Pawar, Sujay Srinivas, Prabhat Bhargava, Seema Gulia, Vanita Noronha, Amit Joshi, Kumar Prabhash, Shripad Banavali, Rajiv Sarin, Rajendra Badwe, Sudeep Gupta
Background Olanzapine is an effective antiemetic agent but it results in substantial daytime somnolence when administered at the standard dose. Our aim was to compare the efficacy of low-dose versus standard-dose olanzapine after highly emetogenic chemotherapy in patients with solid tumours. Methods This was a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trial done in
-
Cancer misinformation puts patients in harm's way Lancet Oncol. (IF 51.1) Pub Date : 2024-01-11 Bryant Furlow
Abstract not available
-
Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study Lancet Oncol. (IF 51.1) Pub Date : 2024-01-11 Mike M Sathekge, Ismaheel O Lawal, Chandrasekhar Bal, Frank Bruchertseifer, Sajana Ballal, Giuseppe Cardaci, Cindy Davis, Mathias Eiber, Türkay Hekimsoy, Otto Knoesen, Clemens Kratochwil, Nat P Lenzo, Johncy Mahapane, Letjie C Maserumule, Amanda H Mdlophane, Kgomotso M G Mokoala, Honest Ndlovu, Vineet Pant, Hendrik Rathke, Janet Reed, Alfred Morgenstern
Background Actinium-225 (225Ac) prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) is a novel therapy for metastatic castration-resistant prostate cancer (mCRPC). We aimed to report the safety and antitumour activity of 225Ac-PSMA RLT of mCRPC in a large cohort of patients treated at multiple centres across the world. Methods This retrospective study included patients treated at seven
-
Targeted alpha therapy: a new tool for advanced prostate cancer Lancet Oncol. (IF 51.1) Pub Date : 2024-01-11 Kalevi Kairemo
Abstract not available
-
Effect of carvedilol versus placebo on cardiac function in anthracycline-exposed survivors of childhood cancer (PREVENT-HF): a randomised, controlled, phase 2b trial Lancet Oncol. (IF 51.1) Pub Date : 2024-01-09 Saro H Armenian, Melissa M Hudson, Lanie Lindenfeld, Sitong Chen, Eric J Chow, Steven Colan, Willem Collier, Xiaohong Su, Edward Marcus, Meagan Echevarria, Aleksi Iukuridze, Leslie L Robison, F Lennie Wong, Ming Hui Chen, Smita Bhatia
Background Carvedilol improves cardiac function in patients with heart failure but remains untested as cardioprotective therapy in long-term childhood cancer survivors (ie, those who have completed treatment for childhood cancer and are in remission) at risk for heart failure due to high-dose anthracycline exposure. We aimed to evaluate the activity and safety of low-dose carvedilol for heart failure
-
Secondary prevention of anthracycline cardiotoxicity in childhood cancer survivors Lancet Oncol. (IF 51.1) Pub Date : 2024-01-09 Jan M Leerink, Elizabeth A M Feijen
Abstract not available
-
Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial Lancet Oncol. (IF 51.1) Pub Date : 2024-01-08 Lei Fan, Zhong-Hua Wang, Lin-Xiaoxi Ma, Song-Yang Wu, Jiong Wu, Ke-Da Yu, Xin-Yi Sui, Ying Xu, Xi-Yu Liu, Li Chen, Wen-Juan Zhang, Xi Jin, Qin Xiao, Ruo-Hong Shui, Yi Xiao, Han Wang, Yun-Song Yang, Xiao-Yan Huang, A-Yong Cao, Jun-Jie Li, Zhi-Ming Shao
Background Triple-negative breast cancers display heterogeneity in molecular drivers and immune traits. We previously classified triple-negative breast cancers into four subtypes: luminal androgen receptor (LAR), immunomodulatory, basal-like immune-suppressed (BLIS), and mesenchymal-like (MES). Here, we aimed to evaluate the efficacy and safety of subtyping-based therapy in the first-line treatment
-
Developing therapies for triple-negative breast cancer subtypes Lancet Oncol. (IF 51.1) Pub Date : 2024-01-08 Alicia Okines, Nicholas Turner
Abstract not available
-
Stereotactic body radiotherapy for primary renal cell carcinoma: a systematic review and practice guideline from the International Society of Stereotactic Radiosurgery (ISRS) Lancet Oncol. (IF 51.1) Pub Date : 2024-01-02 Shankar Siva, Alexander V Louie, Rupesh Kotecha, Melissa N Barber, Muhammad Ali, Zhenwei Zhang, Matthias Guckenberger, Mi-Sook Kim, Marta Scorsetti, Alison C Tree, Ben J Slotman, Arjun Sahgal, Simon S Lo
Surgery is the standard of care for patients with primary renal cell carcinoma. Stereotactic body radiotherapy (SBRT) is a novel alternative for patients who are medically inoperable, technically high risk, or who decline surgery. Evidence for using SBRT in the primary renal cell carcinoma setting is growing, including several rigorously conducted prospective clinical trials. This systematic review
-
When less is more—reducing complexity in cancer trials Lancet Oncol. (IF 51.1) Pub Date : 2024-01-02 Timil H Patel, Donna R Rivera, Harpreet Singh, Paul G Kluetz
Abstract not available
-
Correction to Lancet Oncol 2020; 21: 671–84 Lancet Oncol. (IF 51.1) Pub Date : 2024-01-02
Abstract not available
-
Nigerian competition watchdog fines British American Tobacco Lancet Oncol. (IF 51.1) Pub Date : 2024-01-05 Talha Burki
Abstract not available
-
Commercial determinants of cancer Lancet Oncol. (IF 51.1) Pub Date : 2024-01-02
Abstract not available
-
Serum hormone concentrations and individualisation of breast cancer prevention Lancet Oncol. (IF 51.1) Pub Date : 2024-01-02 Saranya Chumsri
Abstract not available
-
Mitotane and the myth of 14 mg/L Lancet Oncol. (IF 51.1) Pub Date : 2024-01-02 Matthew I Ehrlich, Brian W Labadie, Susan E Bates, Tito Fojo
Abstract not available
-
Universal testing of cutaneous sebaceous carcinoma: a missed opportunity in Lynch syndrome detection Lancet Oncol. (IF 51.1) Pub Date : 2024-01-02 Neil Rajan, Sam Cook, Katie Best, , Kevin Monahan
Abstract not available
-
Correction to Lancet Oncol 2024; 25: e6–17 Lancet Oncol. (IF 51.1) Pub Date : 2024-01-02
Abstract not available
-
Shortages of essential cancer medicines: who is responsible and what are the possible solutions? Lancet Oncol. (IF 51.1) Pub Date : 2024-01-02 Kristina Jenei, Mark P Lythgoe, Kerstin N Vokinger
Abstract not available
-
Dignity and inequality at the end of life Lancet Oncol. (IF 51.1) Pub Date : 2024-01-02 Robert Stirrups
Abstract not available